Recently, BeiGene Ltd’s lymphoma treatment Brukinsa was approved by the U.S. Food and Drug Administration. This is the first time a drug developed predominantly in China by a Chinese biopharma sponsor has been approved within America. The key clinical trials...
Mantle Cell Lymphoma
Category
BeiGene’s Brukinsa for Mantle Cell Therapy Approved by the FDA Tested Primarily in China
$12,935 for a 30-day supply
UC San Diego Discovered Cirmtuzumab in Phase I/2 Clinical Trial Testing in CLL and MCL Patients in Combo with Imbruvica
A Phase I clinical trial, which has focused on patients with chronic lymphocytic leukemia (CLL) and a half dozen patients with mantle cell lymphoma (MCL), will now expand to include more MCL patients. The study combines an antibody discovered at University of...
MD Anderson Develops Drug IACS-10759 from Concept to Phase I
An MD Anderson-developed drug looks to be effective in overcoming ibrutinib resistance in mantle cell lymphoma. The University of Texas, MD Anderson Cancer Center led a study demonstrating how a small molecule drug discovered at the institution may help overcome...
Feasibility of Posttransplant Velcade (Takeda) in Mantle Cell Lymphoma Needs Further Study
The recent phase 2 CALGB 50403 clinical trial reveals that treatment with either consolidation therapy (to kill any cancer cells that may be let in the body), or maintenance therapy (to help keep cancer from coming back) with Takeda’s Velcade (bortezomib), following...
Chinese Research: TP53, WHSC1 Mutations Key to MCL Prognosis
Targeted Oncology’s Jason Harris, Mutations of TP53 and WHSC1 predicted poorer overall survival (OS) in patients with mantle cell lymphoma (MCL), according to results from next-generation whole-exome sequencing of 16 Chinese patients.1 The presence of these mutations...